New CBO reports estimated potential savings of removing the Medicaid rebate cap and a federal judge dismissed the 340B case on contract pharmacies.

The House proposed removing Medicaid drug rebate caps as a provision in the COVID-19 relief package and Senator Klobuchar introduced new antitrust legislation that could impact the pharmaceutical industry.

The CBO released their simulation model for the budgetary impact of drug price negotiations and KFF published a new analysis that compares drug price increases to the rate of inflation.

The Biden administration continues to overturn Trump's rules, while state lawmakers introduce their own drug pricing policies.

During the first week of the new Biden administration, President Biden has started to reverse some of Trump's drug pricing work.

The Senate Finance Committee released the findings from a two-year investigation into insulin manufacturers and PBMs while senate leadership has confirmed they will prioritize lowering drug prices.

Multiple stakeholders have highlighted the significant amount of drug pricing reform that the Biden administration will soon be able to make, including freezing harmful rules from the Trump administration that have yet to take effect.

President Trump's Most Favored Nation demo has been slowed down by lawsuits, while his executive order to lower insulin costs has been finalized to go into effect later this month.

CMS published the National Health Expenditures for 2019 and approved a final rule to encourage value-based pricing.

The Supreme Court delivered their ruling on Rutledge v Pharmacy Care Management and a 340B administrative dispute resolution rule was published in the Federal Registrar.

Major trade associations are pushing back against Trump's Most Favored Nation rule and large drug manufacturers continue to limit their participation in the 340B discount program.

Canadian officials responded to Trump's importation rule with their own order and a recent analysis shows how much the Unapproved Drugs Initiative has cost the US health care system.

The Trump administration released two rules to lower prescription drug prices and PhRMA has filed an official complaint regarding the previous importation rule.

Maryland Federal District Court ruled on the Medicaid Drug Rebate Program and the Supreme Court heard arguments to overturn the Affordable Care Act.

Just days after Vice President Biden won the presidential election, a COVID-19 vaccine was announced and the Supreme Court plans to hear arguments on the ACA.

The final rule on price transparency was released and a drug price watchdog reported that generic drug prices are beginning to rise.

The first FDA approved COVID-19 treatment may not be as effective as the high price tag makes it out to be and COVID-19 vaccines are expected to be free for everyone once approved.

The Government Accountability Office (GAO) confirmed they will review the legality of Trump's drug discount cards and Biden announced a drug pricing plan similar to Germany's model.

The Supreme Court heard arguments to allow states to regulate PBMs and the RAND corporation compared insulin prices in the US to 32 other OECD countries.

Drug company CEOs met with House Oversight and Reform Committee to discuss high drug prices; House democrats argued that Trump's $200 drug discount cards are election bribes; and President Trump tested positive for COVID-19.

Most of President Trump's plans to lower drug prices will not take effect until after the election and recent studies show they will do little to actually lower costs.

Congress urged HHS to protect the 340B program while President Trump announced he will lower drug prices with discount cards for seniors.

President Trump released his most favored nation executive order and 340B Health threatened legal action against the drug manufacturers that have limited their 340B discounts.

President Trump plans to meet with pharmaceutical executives to discuss his upcoming executive order, meanwhile drug manufacturers are using his July drug pricing executive orders to defend their withdrawal from the 340B program.

Pharmaceutical executives suggested biased alternatives to President Trump's upcoming most favored nation executive order and a recent AHIP survey found that while individuals support Trump's intention to lower drug prices, they do not support his rebate rule.